Cohance Lifesciences shareholding pattern

COHANCE

305.4

9.70 (-3.08%)
Last updated on 20 Feb, 2026 | 15:54 IST
alert_iconwatchlist_icon
BUYSELL
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Cohance Lifesciences Shareholding Pattern

  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

57.49%

Mutual Fund

17.36%

Insurance

3.94%

Foreign Institutional Investors

6.01%

Domestic Institutional Investors

0.29%

Retail

14.92%

Others

-0.01%

Total Promoters
MAR '25
50.1%
JUN '25
66.41%
SEP '25
57.49%
DEC '25
57.49%

Summary

For Year 2025-26, Cohance Lifesciences reports the following shareholding: Total Promoters at 57.49%, Mutual Fund at 17.36%, Insurance at 3.94%, Foreign Institutional Investors at 6.01%, Domestic Institutional Investors at 0.29%, and Retail at 14.92%. This breakdown provides a quick snapshot of ownership distribution for Cohance Lifesciences in 2025-26.

Cohance Lifesciences FAQs

As of 02-2026, the promoter shareholding in Cohance Lifesciences stands at 57.49% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Cohance Lifesciences is 6.01% and 0.29% respectively.

The retail shareholding of the Cohance Lifesciences is 14.92%.

Changes in shareholding patterns of Cohance Lifesciences can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Cohance Lifesciences are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost